Officials toss Genentech antibody patent

Genentech says the U.S. Patent Office has rejected a patent covering the way it uses recombinant DNA technology to make antibodies. The biotech giant says it uses the 415 patent in making a number of therapies, has licensing agreements on the technology covered in the patent and earns royalties on claims to the patent. The Patent Office's decision came after Genentech asked it to reexamine the issue after patent officials originally rejected 36 patent claims. Genentech says it may appeal.

- see this release
- check out the AP story

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."